Aviragen Therapeutics (AVIR) Misses Q4 EPS by 4c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.47), $0.04 worse than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hub Group faces credibility test as Q2 report looms Sept. 1
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56